IMMUNE DESIGN CORP. (NASDAQ:IMDZ) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07. Submission of Matters to a Vote of Security Holders.
On June 13, 2018, Immune Design Corp. (the “Company”) held its 2018 annual meeting of stockholders (the “Annual Meeting”). The final results for each of the proposals submitted to a vote of the Company’s stockholders at the Annual Meeting are set forth below. The proposals set forth below are described in detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on April 26, 2018.
Proposal 1: The Company’s stockholders elected the Board’s two nominees as Class I directors to serve on the Board, with Ed Penhoet, Ph.D. to serve as Chairman of the Board, until the 2021 annual meeting of stockholders, or until their successors are duly elected and qualified, by the votes set forth in the table below:
|
Nominee |
Votes For |
Votes Withheld |
Broker Non-Votes |
|
Ed Penhoet, Ph.D. |
32,109,434 |
2,727,786 |
10,450,333 |
|
David Baltimore, Ph.D. |
32,107,691 |
2,729,529 |
10,450,333 |
Proposal 2: The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2018 by the votes set forth in the table below:
|
Votes For |
Votes Against |
Abstain |
|
44,967,821 |
296,242 |
23,490 |
Proposal 3: The Company’s stockholders approved the stock option exchange program by the votes set forth in the table below:
|
Votes For |
Votes Against |
Abstain |
Broker Non-Votes |
|
26,328,685 |
8,094,988 |
413,547 |
10,450,333 |
About IMMUNE DESIGN CORP. (NASDAQ:IMDZ)
Immune Design Corp. is a clinical stage immunotherapy company. The Company focuses on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company is developing multiple product candidates from its discovery platforms, including ZVex and GLAAS. ZVex is a discovery platform that uses a vector to generate product candidates designed to create cytotoxic T cells (CTLs) in vivo. The ZVex vector is a delivery system based on a hybrid, re-engineered virus designed to carry the genetic information of selected tumor antigen in whole or selected epitopes selectively to dendritic cells (DCs) in the skin. When injected into a cancer patient, a ZVex-based product candidate is designed to interact only with these DCs, delivering the tumor antigen in the form of ribonucleic acid (RNA). GLA Adjuvant Systems (GLAAS) is a discovery platform that works in vivo and is based on a synthetic molecule called glucopyranosyl lipid A (GLA).
